Increased ovarian cancer risk not found in women with breast cancer family history

September 20, 2005

NEW YORK, September 21, 2005 - Women with a strong family history of breast cancer but who don't have breast cancer genetic mutations can now be reassured that they are not at increased risk for ovarian cancer, according to a new study by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). The work, published in the September 21, 2005, issue of the Journal of the National Cancer Institute, is one of the first prospective studies to allow doctors to tailor ovarian cancer screening recommendations for women with a family history of breast cancer but with no identifiable BRCA mutation.

In the ten years since the discovery of BRCA1 and BRCA2 genes, it has been learned that the risk for ovarian cancer in families with mutations in these genes is increased 6- to 61-fold. However, it has also emerged that up to half of families with multiple cases of breast cancer do not have mutations in either BRCA1 or BRCA2. Up until the current study, there has been limited data with which to inform such families as to their risk for ovarian cancer.

The MSKCC Clinical Genetics Service studied 199 families with multiple cases of breast cancer but no identified BRCA mutation. During follow-up, 19 new cases of breast cancer were diagnosed - three times more than the six cases that were expected. Only one case of ovarian cancer was diagnosed, which is what researchers would have anticipated in an average risk population.

While the authors conclude that women from these families do not have an increased risk of ovarian cancer, they also indicate that the genetic mechanism for up to half of hereditary breast cancer remains unknown. Ongoing research at MSKCC, in collaboration with other scientists in the US, Canada, and Israel, is underway to map undiscovered genes associated with hereditary breast cancer.
The lead author of the study is Noah D. Kauff, MD, a gynecologist in the Clinical Genetics Service at MSKCC. The senior author is Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at MSKCC.

This research was supported by the Department of Defense Breast Cancer Research Program, the Koodish Fellowship Fund, the Lucius L. Littauer Foundation, the Frankel Foundation, and MSKCC's Prevention, Control, and Population Research Program. Funding to pay the Open Access publication charges for this article was provided by MSKCC's Prevention, Control, and Population Research Program.

Memorial Sloan Kettering Cancer Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to